On-column virus inactivation by solvent/detergent treatment for a recombinant biological product.
Anion-exchange chromatography
Process intensification
Process performance
Solvent/detergent inactivation
Viral clearance study
Virus infectivity
Journal
Biologicals : journal of the International Association of Biological Standardization
ISSN: 1095-8320
Titre abrégé: Biologicals
Pays: England
ID NLM: 9004494
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
10
03
2023
revised:
05
05
2023
accepted:
14
07
2023
medline:
15
9
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
ppublish
Résumé
Each process step in the manufacture of biological products requires expensive resources and reduces total process productivity. Since downstream processing of biologicals is the main cost driver, process intensification is a persistent topic during the entire product life cycle. We present here one approach for the intensification of bioprocesses by applying on-column virus inactivation using solvent/detergent (S/D) treatment during ion-exchange chromatography. The established purification process of a recombinant protein was used as a model to compare key process parameters (i.e., product yield, specific activity, impurity clearance) of the novel approach to the standard process protocol. Additional wash and incubation steps with and without S/D-containing buffers were introduced to ensure sufficient contact time to effectively eliminate enveloped viruses and to significantly decrease the amount of S/D reagents. Comparison of key process parameters demonstrated equivalent process performance. To assess the viral clearance capacity of the novel approach, XMuLV was spiked as model virus to the chromatographic load and all resulting fractions were analyzed by TCID
Identifiants
pubmed: 37516085
pii: S1045-1056(23)00031-3
doi: 10.1016/j.biologicals.2023.101693
pii:
doi:
Substances chimiques
Detergents
0
Biological Products
0
Solvents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101693Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors were employees of Baxalta Innovations GmbH (part of Takeda) or Takeda Manufacturing Austria AG at the time of this study. Andreas Flicker, Christian Fiedler, Maria R. Farcet, Martin Purtscher, and Thomas R. Kreil are Takeda stock owners. Daniel Polasek is currently employee of Octapharma Pharmazeutika Produktionsges.m.b.H (Oberlaaer Straβe 235, 1100 Vienna, Austria).